APT, a leading manufacturer and supplier of EP and Vascular Intervention medical devices, is committed to advance the interventional medical field utilizing technologies and innovations.
From its inception in 2002, APT is persistent in continuous investment in R&D, which lays the foundation for the success and continued expansion of our technology and growing market share. APT has been collaborating with clinicians, universities, and hospitals to develop innovative products and solutions that empower clinicians to improve patient care. APT's growing product portfolio covers Electrophysiology, Cardiology, Peripheral, and Neuro intervention. Including Electrophysiology Mapping Catheter, Ablation Catheter, The Electrophysiology Recording System, Transseptal Needle and Sheath. In the cardiology and peripheral interventional fields, we have Hemostasis Introducer, Hydrophilic Guidewire, Hydrophilic Angiographic Catheter, PTCA guidewire, PTCA balloon catheter, Guiding catheter, Guiding extension catheter, Aspiration catheter, Microcatheter, etc.
In the Electrophysiology field, we are the first domestic manufacturer in China to obtain market access for the clinical application of Electrophysiological Catheter, Steerable Ablation Catheter, Floating Temporary Pacing Catheter, which extremely advanced the development of the Electrophysiology field in China. In the field of vascular intervention, the Guide Extension Catheter and Thin-walled Sheath are the only products approved for marketing in China.
By the end of 2020, the company has a total of 70 domestic and foreign patents，including 41 domestic invention patents and 2 foreign invention patents. Meanwhile, it has 37 domestic medical device registration certificates or filing certificates, of which 33 are Class III medical devices. We also have 14 CE certificates and completed the registration in more than 10 other countries and regions.
In 2020, the company's market share has been further increased, APT's products cover 31 provincesand more than 1300 medical centers in China, and has been sold to 85 countries and regions, including Europe, Asia Pacific, Middle East, and Latin America. APT is dedicated to being a leader in the interventional field while protecting the health of humanity.
| Full name | APT Medical Inc. |
|---|---|
| Abbreviations | APT |
| Code | 688617 |
| Founded | 2002-06-17 |
| Listing | 2021-01-07 |
| Domicile | Room 601, Building B, Tongfang Information Port, No.11 Langshan Road, Nanshan District, Shenzhen, P.R. of China |
| Website | http://www.aptmed.com/ |
| ir@aptmed.com | |
| STAR Theme | Biopharmaceutical and specialized equipment manufacturing |
| CSRC Sector | Specialized Equipment Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 2.22 | 1.65 | 0.43 |
| R&D expenditure as a % of operating revenue | 15.00 | 17.43 | 22.08 |
| Operating Revenue | 479,436,312.40 | 403,963,580.32 | 241,722,809.86 |
| Net Income | 104,194,846.75 | 78,075,293.91 | 16,674,769.22 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 479.44 | 403.96 | 241.77 |
| Operating Costs | 142.13 | 117.89 | 75.48 |
| Operating Income | 119.45 | 92.09 | 23.60 |
| Pretax Income | 121.21 | 91.36 | 23.21 |
| Income Tax | 17.02 | 13.28 | 6.54 |
| Net Income | 104.19 | 78.08 | 16.67 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 350.26 | 274.34 | 207.21 |
| Non-current Assets-Total | 238.45 | 286.69 | 118.61 |
| Total Assets | 588.71 | 561.03 | 325.82 |
| Liabilities | |||
| Current Liabilities-Total | 109.41 | 101.46 | 48.51 |
| Non-current Liabilities-Total | 29.21 | 113.67 | 6.62 |
| Total Liabilities | 138.62 | 215.13 | 55.12 |
| Stockholder's Equity | |||
| Share Capital | 50.00 | 50.00 | 29.44 |
| Retained Profits | 238.91 | 139.74 | 121.47 |
| Total Owners' Equity | 450.09 | 345.90 | 270.70 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 148.24 | 54.90 | 18.63 |
| Net Cash Flows-Investing | 0.73 | -68.02 | -28.61 |
| Net Cash Flows-Financing | -101.62 | -3.23 | 20.90 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| Zhenghui Cheng | 16.69 | 25.03% |
| Ling Cheng | 5.00 | 7.50% |
| Qiming Weichuang (Shanghai) Private Equity Investment Centre L.P. | 2.81 | 4.22% |
| QM33 LIMITED | 2.75 | 4.12% |
| Shenzhen Huishen Enterprise Management Center (Limited Partnership) | 2.50 | 3.75% |
| Suzhou Industrial Park Qihua III Investment Centre L.P. | 2.27 | 3.40% |
| Suzhou Industrial Park Qiming Rongke Equity Investment L.P. | 2.20 | 3.30% |
| Suzhou Qiming Chuangzhi Equity Investment L.P. | 2.19 | 3.28% |
| Nantong Fuxing Enterprise Management Center (Limited Partnership) | 2.12 | 3.18% |
| Yiqing Xu | 2.00 | 3.00% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.